Table 1: Postoperative morbidity-mortality database in patients with peritoneal surface malignancy treated by cytoreductive surgery, hyperthermic intraperitoneal cisplatin and doxorubicin, and simultaneous intravenous ifosfamide. Eight categories of events and 47 adverse outcomes were scored.

Category Adverse event Gastrointestinal Anastomotic failure Fistula Pancreatic fistula Pancreatitis Bile leak from liver surface Hartmann pouch blowout Enterostomy tube complication Oral pain/ulceration Nausea/vomiting Diarrhea Ascites Other Pulmonary Respiratory distress Pleural effusion Pneumonia ARDS Chest tube removal Other Intravenous catheter status Line sepsis Line thrombosis Insertion pneumothorax Total parenteral nutrition intolerance Other Cardiovascular Rhythm Hypotension Ischemia Pulmonary embolism Thrombophlebitis Venous thrombosis Pulmonary edema 5-Fluorouracil cardiac toxicity Other Genitourinary Urinary tract infection Urine leak Other Hematological WBC Platelets Postoperative hemorrhage Units of fresh-frozen plasma Other Neurotoxicity State of communication Orientation/intellect Stroke Other Infection Intra-abdominal infection Wound infection Other

ARDS: acute respiratory distress syndrome; WBC: white blood cell count.